Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co Debt-to-Asset Chart
Joincare Pharmaceutical Group Industry Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co Debt-to-Asset vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a Debt-to-Asset of 0.11 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors.
Is Joincare Pharmaceutical Group Industry Co's Debt-to-Asset too high?
Joincare Pharmaceutical Group Industry Co's current Debt-to-Asset is 0.11. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's Debt-to-Asset compare to ZTS?
Joincare Pharmaceutical Group Industry Co's Debt-to-Asset of 0.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. Joincare Pharmaceutical Group Industry Co's current Debt-to-Asset is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a current Debt-to-Asset of 0.11. The stock's GF Value™ is $9.20, compared to a current price of $8.00 — trading 13% below its estimated fair value. The current Debt-to-Asset is 0.11. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (XSWX:JCARE), the current Debt-to-Asset is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of $8.00 is trading 13% below its estimated GF Value™ of $9.20.
Key valuation signals for XSWX:JCARE:
Debt-to-Asset: 0.11
GF Value™: $9.20 vs. price of $8.00 (13% below fair value)
No single metric tells the full story. See the XSWX:JCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for XSWX:JCARE
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:JCARE has been successfully added to your 
